A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
Status:
Active, not recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
TGFβ has profound local immunosuppressive and immunoexclusion effects in the tumor
microenvironment that are integrally involved in the failure of immune checkpoint inhibitors
in some tumors. Preclinical data in a variety of models strongly support the study of AVID200
in patients with treatment-refractory advanced and metastatic malignancies as an approach to
reducing immunosuppression/exclusion and increasing the activity of immune checkpoint
inhibitors.